Graded Prognostic Assessment for Gastrointestinal Cancer (GI-GPA)

ورودی‌های بالینی بیمار

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
gi gpa score
—points
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Poor Prognosis0–1
  • Intermediate-Poor Prognosis1.5–2
  • Intermediate Prognosis2.5–3
  • Good Prognosis3.5–4
Direct Clinical Answer

The Graded Prognostic Assessment for Gastrointestinal Cancer (GI-GPA) calculates staging malignant disease, estimating overall survival, and assessing chemotherapy tolerability. Key inputs include age category. Scores guide adjusting systemic antineoplastic regimens, planning supportive palliative measures, or targeted monitoring. This standardized assessment improves clinical decision safety and bedside patient management.

Clinical Guidelines & Evidence

Estimates survival in patients with gastrointestinal cancers and brain metastases. Uses 4 prognostic factors to provide risk stratification and guide treatment decisions for patients with brain metastases from GI cancers.

Clinical Indication

The Graded Prognostic Assessment for Gastrointestinal Cancer (GI-GPA) is indicated for bedside clinical practice to support Estimates survival in patients with gastrointestinal cancers and brain metastases. Uses 4 prognostic factors to provide risk stratification and guide treatment decisions for patients with brain metastases from GI cancers.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients with solid tumors or hematologic malignancies undergoing staging, systemic therapy tolerability assessment, or prognostic stratification. Clinical application is indicated across Medical oncology clinics, chemotherapy infusion suites, inpatient oncology services, and palliative care.

Limitations & Contraindications

Prognostic indices provide statistical cohort survival estimates and must not replace individualized patient goals of care.

Clinical Pearls & Action Plan

Standardized functional performance status (ECOG or Karnofsky) is an independent determinant of chemotherapy tolerance and survival. Guideline pearl: Helps guide treatment selection and end-of-life decision-making.

Formula & Variables:

GI-GPA Score = Age points (0-0.5) + KPS points (0-2) + Extracranial metastases points (0-0.5) + Number of brain metastases points (0-1)

Input Parameters

NameTypeRequiredDescription
age_categorystringYesPatient age category with different prognostic implications(years)
kpsstringYesKarnofsky Performance Status reflecting functional capacity
extracranial_metastasesstringYesPresence of extracranial metastases outside the brain
number_brain_metastasesstringYesNumber of brain metastases identified on imaging

Score Interpretation & Guidance

RangeStageDescription
0–1Poor PrognosisWorst survival group
1.5–2Intermediate-Poor PrognosisBelow average survival
2.5–3Intermediate PrognosisAverage survival
3.5–4Good PrognosisBest survival group

Evidence-Based References (EBM)

  • Sperduto PW, Mesko S, Li J, Cagney D, Aizer A, Lin NU, et al. Estimating survival in patients with gastrointestinal cancers and brain metastases: An update of the graded prognostic assessment for gastrointestinal cancers (GI-GPA). Clin Transl Radiat Oncol. 2019;18:39-45. doi: 10.1016/j.ctro.2019.06.009.DOI: 10.1016/j.ctro.2019.06.009
  • Sperduto PW, Chao ST, Sneed PK, Luo X, Suh J, Roberge D, et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. Int J Radiat Oncol Biol Phys. 2010;77(3):655-61. doi: 10.1016/j.ijrobp.2009.08.025.DOI: 10.1016/j.ijrobp.2009.08.025
  • Sperduto PW, Yang TJ, Beal K, Pan H, Brown PD, Bangdiwala A, et al. Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA). JAMA Oncol. 2017;3(6):827-831. doi: 10.1001/jamaoncol.2016.3834.DOI: 10.1001/jamaoncol.2016.3834

Related calculators